Randomized, open-label, phase II study comparing the efficacy and the safety of cabazitaxel versus weekly paclitaxel given as neo-adjuvant treatment in patients with operable Triple Negative or luminal B/HER2 normal Breast Cancer

Trial Profile

Randomized, open-label, phase II study comparing the efficacy and the safety of cabazitaxel versus weekly paclitaxel given as neo-adjuvant treatment in patients with operable Triple Negative or luminal B/HER2 normal Breast Cancer

Completed
Phase of Trial: Phase II

Latest Information Update: 03 Aug 2017

At a glance

  • Drugs Cabazitaxel (Primary) ; Cyclophosphamide; Epirubicin; Paclitaxel
  • Indications Breast cancer
  • Focus Therapeutic Use
  • Acronyms GENEVIEVE
  • Most Recent Events

    • 30 Jul 2017 The protocol has amended for epirubicin and cyclophosphamide treatment sequence to taxane during recruitment because of low recruitment and in case of TNBC monotherapy prior to surgery was not accepted, according to results published in the European Journal of Cancer
    • 30 Jul 2017 Results published in the European Journal of Cancer
    • 10 Jun 2017 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top